by Manon FRACHON | 14 Apr Tue | Without category
Proceeds from the financing will support the advancement of three first- and best-in-class ADC[1] programs through upcoming key clinical milestones While oncology continues to face substantial and largely unmet needs, Jeito will leverage its expertise to accelerate...
by Manon FRACHON | 11 Mar Wed | Without category
Samit Hirawat, M.D., brings over 25 years of senior leadership and clinical development experience at top-tier international pharmaceutical groups, including Novartis and Bristol Myers Squibb, further enhancing Jeito’s strategic capabilities. His expertise will...
by Manon FRACHON | 24 Feb Tue | Without category
Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program ALV‑100 designed to deliver potent, durable weight loss and long‑term maintenance with improved tolerability. The financing will also support Investigational New Drug...
by Manon FRACHON | 15 Oct Wed | English
Paris, France, October 15th, 2025 – Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to biopharma, today announced the promotion of Ksenija Pavletic to General Partner, reinforcing the firm’s senior leadership team as it continues to...
by Manon FRACHON | 10 Sep Wed | English
Investment will support Odyssey’s portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases. Jeito will leverage its global network, expertise and strong value creation track record in immunology and...
Recent Comments